S&P Up 10% Already in 2026: Where Do LEAPS Go From Here?

Ten percent in less than a year — again. The S&P 500 (SPY) keeps compounding like it's 1999, and the financial media keeps publishing the same article: long-term investors should hold, diversify, and not panic. Solid advice for your 401(k). Useless for anyone trying to find the next asymmetric trade. Here's the contrarian reality: a market that's already priced in optimism is exactly the environment where deep out-of-the-money LEAPS calls on beaten-down or under-owned large-caps become structurally attractive. Not because the market crashes — but because when compressed premium meets a single catalyst, the math gets violent in your favor. The crowd is congratulating itself. That's usually when you start doing your homework.

What's Actually Happening

Strip away the headline number and you'll find a market running on fumes of valuation expansion, not earnings growth. The S&P 500's forward P/E has crept back above 21x — a level that, historically, has preceded either a prolonged sideways grind or a sharp mean-reversion event. Neither is a gift to passive index holders. What's more telling is the dispersion underneath the surface: a handful of mega-cap technology names are doing the heavy lifting, while broad market breadth has quietly deteriorated through stretches of 2025 and into 2026.

The bull case is real — U.S. corporate earnings have been resilient, AI infrastructure spending is accelerating, and the Fed has been threading a soft-landing needle with surgical precision. But resilience isn't the same as cheap. When the market prices in the best-case scenario across multiple variables simultaneously, you get an index at all-time highs with virtually no margin of safety. That's not a reason to short SPY (SPY). It is a reason to think carefully about where the next 20%–40% move in individual large-caps is hiding — because the index itself is unlikely to deliver that kind of return from here without a serious catalyst reshuffling.

Historically, markets that post 25%+ gains over a two-year stretch tend to see one of two things: a consolidation period that lasts 12–18 months, or a rotation so sharp it catches most retail traders completely flat-footed. Both scenarios create opportunity — if you're positioned correctly before the move, not after.

Why Options Traders Should Pay Attention

Here's where it gets interesting. When the broader market is grinding higher on low volatility, the VIX (VIX) gets suppressed, and implied volatility across the options chain compresses. For premium sellers, that's a problem. For buyers of cheap, deep OTM options on large-caps that haven't fully participated in the rally — it's a window.

Implied volatility is, in essence, the market's pricing mechanism for uncertainty. When the market feels complacent, IV drops. When IV drops, out-of-the-money options get mispriced relative to their actual probability of achieving outsized moves. This isn't theoretical — it's the core mechanic behind why a $0.03 LEAPS call on a large-cap can turn into $1.50 when a sector rotates hard or an earnings revision cycle kicks in.

Right now, several large-cap sectors — healthcare (XLV), energy (XLE), and select industrials — are meaningfully lagging the S&P 500's 2026 returns. Their implied volatility is compressed. Their options premiums are thin. And they're sitting on potential catalysts: drug approvals, energy policy shifts, infrastructure spending cycles. When IV is low and you have a well-researched catalyst thesis, the cost of a two-year LEAPS call on a $40–$80 stock can sit in the $0.01–$0.08 range. That's the strike zone.

The timing dynamic also matters. With the market already up 10% YTD, institutional money managers are increasingly under pressure to justify their active mandates. That creates forced rotation — capital moving out of crowded mega-cap tech trades and into underperforming sectors with better relative value. That rotation is exactly the kind of directional move that turns a cheap LEAPS position into a multi-bagger.

The LEAPS Angle

Let's get specific about the mechanics. Deep OTM LEAPS calls — strikes 30%–60% above the current stock price, expiring 12–24 months out — are not lottery tickets if you've done the work. They're a way to define your maximum loss while maintaining full exposure to a large directional move. In a market where index upside feels capped but individual stock volatility can still be explosive, that structure is exactly what you want.

Consider the setup in a stock like Pfizer (PFE), which has drastically underperformed since its COVID-era highs and is now trading at valuations not seen in over a decade. Or look at energy names like Devon Energy (DVN), where commodity price swings can compress or expand the stock 40%–60% in a single cycle. A LEAPS call purchased when IV is low and the stock is in a multi-month base costs almost nothing in absolute dollar terms. If the catalyst arrives — an FDA approval, an oil supply shock, a shift in Fed policy that reprices rate-sensitive sectors — the move in the underlying can be sudden and substantial.

The challenge is finding these setups before the crowd does. Most retail scanners show you what's already moving. What you actually need is visibility into which large-cap options are sitting at $0.01–$0.08 with realistic catalysts on the horizon — before the IV spike that prices them out of reach. That's the specific problem StrikeEdge is built to solve: surfacing deep OTM LEAPS calls on large-caps where the premium is still thin but the thesis has teeth. When the market is complacent and the index feels extended, that's when the scanner earns its keep.

The realistic scenario isn't that every one of these positions pays off — it's that a portfolio of three to five well-researched setups, each risking $50–$150 total, needs only one or two to move to generate significant returns on the capital deployed. That's asymmetric risk management, not speculation.

Key Risks to Watch

None of this comes without a cost. Deep OTM LEAPS have a high probability of expiring worthless — that's the trade-off for the asymmetric upside. If the market continues grinding higher uniformly, the rotation thesis gets delayed, and time decay (theta) will quietly erode positions that don't move.

• IV crush risk: If broader volatility drops further, even correct directional calls can lose value in the short term before the move arrives.
• Catalyst timing: A drug trial delay, an earnings miss, or a macro shock can push your catalyst 12 months further out than expected — and LEAPS don't care about your conviction, only about time.
• Liquidity risk: Deep OTM options on some large-caps have wide bid-ask spreads. Getting in and out cleanly requires patience and limit orders.
• Macro reversal: If the Fed pivots hawkish unexpectedly or a credit event surfaces, broad market selling pressure can overwhelm individual stock theses — even good ones.

Position sizing is the discipline that separates traders who survive from those who don't. Never allocate more than you're genuinely comfortable losing entirely on any single LEAPS position.

The S&P 500 being up 10% in 2026 is not a reason to chase the index — it's a signal to look harder for the positions the crowd isn't crowding into yet. Compressed IV, lagging sectors, and credible catalysts are all present in this market right now. The work is identifying which large-cap LEAPS are priced at a discount to their actual optionality. Do that research systematically, size positions conservatively, and the math of asymmetric payoffs can work in your favor — regardless of what the index does next.